References:
1. Buse DC, Manack AN, Fanning KM et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache: The Journal of Head and Face Pain . 2012;52:1456-70.
2. Durham PL. Calcitonin gene-related peptide (CGRP) and migraine.Headache . 2006;46 Suppl 1(Suppl 1):S3-S8.
3. Edvinsson L, Haanes KA, Warfvinge K et al. CGRP as the target of new migraine therapies—successful translation from bench to clinic.Nature Reviews Neurology . 2018;14:338-50.
4. Evans RW. Raynaud’s Phenomenon Associated With Calcitonin Gene-Related Peptide Monoclonal Antibody Antagonists. Headache . 2019;59:1360-4.
5. Durham PL. CGRP-receptor antagonists—a fresh approach to migraine therapy? New England Journal of Medicine . 2004;350:1073-5.